Acting Chair Mark Uyeda said he’s directed the SEC to re-evaluate the agency’s proposal expanding the definition of an ...

Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company ...

of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), as well as to terminate its reporting obligations under the Exchange Act. As a result of filing Form 15F, GOL's obligations ...

of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between November 02 ...

of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 1 ...

of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company’s securities between September 28 ...

The document indicates that Alterity Therapeutics is adhering to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 for the month of February 2025. The company has confirmed that it ...

As previously informed, as a result of GOL's Chapter 11 filing, the New York Stock Exchange ("NYSE") suspended ... under applicable U.S. federal securities laws in any way. Special Note Regarding ...